€3.2M Grant awarded: major boost for the launch of our validation study
June 11, 2018
Poster presentation on METAglut1™ our innovative IVD blood test at the meeting of SFNP 2019
January 16, 2019
June 22-24, 2018.
[EVENTS] Company ; METAglut1™
We are thrilled to have our first booth at the 2nd European Conference on GLUT1 Deficiency, hapenning in East Grinstead, UK.
We had the opportunity to share our latest news about the launch of our validation study for METAglut1™.
METAglut1™ is our first IVD blood test to aid the early diagnosis of Glut1 Deficiency Syndrom (Glut1DS), also known as De Vivo Disease, a rare neuro metabolic disorder that can significantly impact the lives of affected children.
We believe our diagnostic tool will enable a significant advancement in identifying the condition, leading to profound implcations for patients and their families. And this annual european meeting was the perfect place to share our latest advancements to the Glut1DS community and foster collaborations among the disease’s specialists.
About the event organizer
Matthews Friends are a UK registered charity, operating since 2014 and specializing exclusively in medical ketogenic dietary therapies. They support patients, families and professionals by providing information, training, research and grants to develop ketogenic services and support systems for drug resistant (refractory) epilepsy as well as other neurological and metabolic disorders, such as GlutDS.
The Conference on Glut1 Deficiency, organized by Matthews Friends, was an opportunity for families and professionals to learn together as well as providing access to professionals working in the field of Glut 1 Deficiency by the families.
Participating in the 2nd European Conference on GLUT1 Deficiency has invigorated our commitment to advancing research and innovation in pediatric health. We are dedicated to collaborating with experts and stakeholders to improve patient outcomes and have the test as fast as possible covered and available.
